Sep 20, 2023 7:30am EDT Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Aug 16, 2023 7:30am EDT Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
Aug 14, 2023 8:00am EDT Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
Jul 31, 2023 9:00am EDT Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
Jun 28, 2023 8:00am EDT Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
Jun 23, 2023 8:00am EDT Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
Jun 20, 2023 8:00am EDT Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
May 10, 2023 7:30am EDT Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
